Dr. Shyr is a Fellow of the American Statistical Association and FDA advisory committee voting member. He has delivered more than 200 abstracts at professional meetings and published more than 400 peer-reviewed papers in a variety of journals (h-index = 83). He is the member of the US National Academy of Medicine (IOM) Committee on Policy Issues in the Clinical Development of Biomarkers for Molecularly Targeted Therapies. He has served as a member of the US National Cancer Institute (NCI) Developmental Therapeutics Study Section, Cancer Immunopathology and Immunotherapy Study Section and the Population and Patient-oriented Training Study Section; he also has served on the epidemiology section of the U.S. Army Medical Research and Materiel Command Breast Cancer Research Program (BCRP), and Dr. Shyr is the co-course director for the AACR/ASCO Methods in Clinical Cancer Research Vail Workshop. In addition, he has presented workshops worldwide, in countries such as Belgium, Canada, Germany, China, Japan, Saudi Arabia, and Taiwan. He currently serves on 14 external advisory boards, is the associate editor of JAMA Oncology and the Journal of Thoracic Oncology, directs the biostatistics/bioinformatics cores for the NCI-funded Vanderbilt University Breast Cancer SPORE and GI Cancer SPORE, and is the principle investigator of the NCI U01 Barrett’s Esophagus Translational Research Network Coordinating Center (BETRNetCC).